Delay in Revenue Recognition Due to Timing Difference in European Approval
An event in which a delay from the planned timing of pharmaceutical approvals in Europe defers the recognition of approval-related royalties, co-promotion revenue and other income to subsequent periods.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.